Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
J W Holch, S Held, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2017
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3
D P Modest, T Denecke, J Pratschke, et al.
Journal of Medical Genetics
|
October 3, 2009
Identification of 11 novel mutations in eight BBS genes by high-resolution homozygosity mapping
H M Harville, S Held, A Diaz-Font, et al.
ESMO Open
|
August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
A H S Alig, D P Modest, S Stintzing, et al.
International Journal of Cancer
|
August 19, 2015
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
A Stahler, V Heinemann, C Giessen-Jung, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
B Kimmel, S T Löhnert, F Wedekink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
Leukemia
|
April 26, 2017
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
S Knop, C Langer, M Engelhardt, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
ESMO Open
|
May 4, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
J W Holch, S Held, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2017
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3
D P Modest, T Denecke, J Pratschke, et al.
Journal of Medical Genetics
|
October 3, 2009
Identification of 11 novel mutations in eight BBS genes by high-resolution homozygosity mapping
H M Harville, S Held, A Diaz-Font, et al.
ESMO Open
|
August 22, 2024
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
A H S Alig, D P Modest, S Stintzing, et al.
International Journal of Cancer
|
August 19, 2015
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
A Stahler, V Heinemann, C Giessen-Jung, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
B Kimmel, S T Löhnert, F Wedekink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
Leukemia
|
April 26, 2017
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
S Knop, C Langer, M Engelhardt, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
ESMO Open
|
May 4, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
Page
of 8